87025-89-6

Basic information

• Product Name: 1,2-Benzenedicarboxylic acid, mono(1-methyl-4-phenylbutyl) ester
• CAS NO: 87025-89-6
• Molecular Formula: C19H20O4
• Molecular Weight: 312.365
• Mol File: 87025-89-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1,2-Benzenedicarboxylic acid, mono(1-methyl-4-phenylbutyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Benzenedicarboxylic acid, mono(1-methyl-4-phenylbutyl) ester(87025-89-6)
• EPA Substance Registry System: 1,2-Benzenedicarboxylic acid, mono(1-methyl-4-phenylbutyl) ester(87025-89-6)

Safety Data

• Hazardous Substances Data: 87025-89-6(Hazardous Substances Data)

Upstream product

• 85-44-9 phthalic anhydride 
• 2344-71-0 5-phenylpentan-2-ol 

Downstream Products

• 1429484-72-9 (S)-5-hydroxy-2-methyl-7-[(R)-5-phenyl-2-pentyloxy]-2,3-dihydroquinolin-4(1H)-one 
• 1429484-73-0 (2S)-1-formyl-5-hydroxy-2-methyl-4-oxo-3-(3-oxobutyl)-7-[(R)-5-phenyl-2-pentyloxy]-2,3-dihydroquinoline 
• 78513-72-1 (6S,6aR)-5,6,6a,7-tetrahydro-1-hydroxy-6-methyl-3-[(R)-5-phenyl-2-pentyloxy]benzo[c]quinoline-9(8H)-one 
• 1429484-74-1 (6S,6aR,10aR)-5,6,6a,7,10,10a-hexahydro-1-acetoxy-6-methyl-3-[(R)-5-phenyl-2-pentyloxy]benzo[c]quinoline-9(8H)-one 
• 77209-75-7 (6S,6aR,9R,10aR)-5,6,6a,7,8,9,10,10a-octahydro-1-acetoxy-9-hydroxy-6-methyl-3-[(R)-5-phenyl-2-pentyloxy]benzo[c]quinoline hydrochloride 
• 2344-71-0 (S)-(+)-5-phenyl-2-pentanol 
• 87068-86-8 C₁₉H₂₀O₄ 
• 1429484-68-3 (S)-5-phenyl-2-pentanol phthalate (S)-α-methylbenzylamine salt 

Relevant articles and documents

Levonantradol: Asymmetric synthesis and structural analysis

The first asymmetric synthesis of a synthetic cannabinoid levonantradol was accomplished, and the 3-D solution structure of its core architecture was confirmed by NMR and computational methods. The Royal Society of Chemistry 2013.

Substituted hexahydropyrrolo[1,2-a]-quinolines, hexahydro-1H-pyrido[1,2-a]-q

Tricyclic benzo fused compounds of the formula STR1 and pharmaceutically acceptable cationic and acid addition salts thereof, wherein n is zero, 1 or 2, and t is 1 or 2; M is CH or N, R1 is H or certain acyl groups; Q is CO2 R4, COR5, C(OR7)R5 R6, CN, CONR9 R10, CH2 NR9 R10, CH2 NHCOR11, CH2 NHSO2 R12, 5-tetrazolyl or when n is 1, Q and OR1 together form a lactone or certain reduced derivatives thereof; and Z is certain alkyl, alkoxy, alkoxyalkyl, aralkyl, aralkoxy, aryloxyalkyl or aralkoxyalkyl groups, are valuable central nervous system active agents, methods for their use, pharmaceutical compositions containing them and certain intermediates therefor.